Integrated Management of Acute and Chronic Cardiovascular Disease
|
|
- Meryl Stevenson
- 5 years ago
- Views:
Transcription
1 12 th International Meeting Integrated Management of Acute and Chronic Cardiovascular Disease ORGANIZERS: KURT HUBER (Austria) HARALD DARIUS (Germany) BERNARD GERSH (USA) OTMAR PACHINGER (Austria) The Spectrum from Prevention to Intervention MAIN TOPICS: Acute Coronary Syndromes Antiplatelet Therapy Anticoagulants Atrial Fibrillation Biomarkers Cardiac Imaging Case Presentations Cardiac Surgery Endstage Coronary Disease Heart Failure Hypertrophic Obstructive CMP Interventional Cardiology Metabolic Diseases and the Heart New Devices STEMI Networks Transcatheter Aortic Valve Implantation (TAVI) Innsbruck, Austria Austria Trend Congress Hotel 1 January 22 25, 2011 FINAL PROGRAM under the auspices of
2 GENERAL INFORMATION Local Organisation Kurt Huber, MD, FESC, FACC Director, 3 rd Department of Medicine Cardiology & Emergency Medicine, Wilhelminenhospital Montleartstrasse 37, A 1160 Vienna, Austria Tel.: (+43/1) , Fax: (+43/1) E mail: kurt.huber@wienkav.at Congress Secretariat Congress and Study Concept GesmbH Widerhoferplatz 4/3/19, A-1090 Vienna, Austria Contact: Ms. Mag. Franziska Beckmann Tel./Fax: (+43/1) csconcept@chello.at Medical Exhibition and Advertising Medizinische Ausstellungs und Werbegesellschaft Freyung 6, A 1014 Vienna, Austria Contact: Ms. Sonja Chmella Tel.: (+43/1) , Fax: (+43/1) maw@media.co.at, Venue Austria Trend Hotel, Innsbruck Rennweg 12a A-6020 Innsbruck Tel. (+43/512) Fax. (+43/512) congress@austria-trend.at Congress Fees: 450. /250. (reduced fee for physicians in education) 2-day attendance: 200. / day attendance: 70. / 135. Internet-Information: 1
3 Saturday, January 22, 2011 Arrivals 19:00 Welcome 20:30 Get-Together-Dinner (Austria Trend Hotel) Sunday, January 23, :00-09:30 Symposium 1: Atrial Fibrillation chairs: S.D. Kristensen (Aarhus, DK) F.W.A. Verheugt (Amsterdam, NL) 08:00-08:30 Pathophysiology and Epidemiology: Is It a Vascular Disease? (B. Gersh, Rochester, USA) 08:30-09:00 Current Status of Future Anticoagulants in Atrial Fibrillation (C. Granger, Durham, US) 09:00-09:30 Ablation Techniques in Atrial Fibrillation: Early and Late Outcomes (M. Borggrefe, Mannheim, DE) 09:30-10:00 Break, Exhibition 10:00-12:00 Symposium 2: Cardiac Imaging chairs: O. Pachinger (Innsbruck, AT) T. Brunner (Wr. Neustadt, AT) 10:00-10:30 Multislice-CT for the Interventionalist (U. Sechtem, Stuttgart, DE) 10:30-10:45 Case #1 (H.-J. Nesser, Linz, AT) 10:45-11:15 Intracoronary Imaging: IVUS, OCT and More (I. Lang, Vienna, AT) 11:15-11:30 Case #2 (H.-J. Nesser, Linz, AT) 11:30-12:00 Angina Pectoris in Patients without Significant CAD Natural History and the Role of Functional Testing (U. Sechtem, Stuttgart, DE) 12:00-12:30 Special Lecture: SCD in HOCM: Risk Stratification, Etiology and Management (M. Borggrefe, Mannheim, D) 12:30-14:00 Lunch Break 2
4 Sunday, January 23, :00-14:00 Moderated Poster Discussion A Moderator: J. Wojta (Vienna, AT) 14:00-15:30 Symposium 3: Cardiac Surgery and the Interface with Cardiology chairs: W. Wijns (Aalst, BE) M. Grabenwöger (Vienna, AT) 14:00-14:20 TAVI Recent Developments (S. Windecker, Berne, CH 14:20-14:35 Case #3 (G. Delle-Karth, Vienna, AT) 14:35-14:55 TAVI or Surgery: The Surgeons View (M. Grimm, Innsbruck, AT) 14:55-15:10 Case #4 (G. Christ, Vienna, AT) 15:10-15:30 Pre-Operative Management of Patients Receiving Dual Antiplatelet Therapy (F.W.A. Verheugt, Amsterdam, NL) 15:30-16:00 Break, Exhibition 16:00-17:30 Symposium 4: Issues in Chronic Heart Failure and Hypertrophic Cardiomopathy chairs: P. Widimsky (Prague, CZ) M. Grimm (Innsbruck, AT) 16:00-16:30 Update In the Management of HOCM: The Role of Medical Therapy, Surgical Myectomy and Alcohol Septal Ablation (B. Gersh, Rochester, USA) 16:30-17:00 Cases #5 and #6 (G. Pölzl, Innbruck, AT) 17:00-17:30 Heart Failure with Preserved Systolic Function: Pathophysiology and Management: More Questions Than Answers (B. Pieske, Graz, AT) 17:30-17:45 Break, Exhibition 3
5 Sunday, January 23, :45-19:00 Satellite Symposium: Dabigatran A New Option in Atrial Fibrillation (sponsored by Boehringer Ingelheim) Moderator: K. Huber (Vienna) 17:45-18:15 Dabigatran Indications and Clinical Practice (S. Conolly, Hamilton, CDN) 18:15-18:45 Will Dabigatran Beat VKA in Daily Routine? Pannel Discussion (chairs and speaker together with F. Andreotti, S. Conolly, C. Granger, B. Gersh, S.D. Kristensen, B. Meier, B. Merkely, F.W.A. Verheugt and P. Widimsky) 18:45-19:00 Discussion 20:30 Faculty Dinner 4
6 Monday, January 24, :00-09:30 Symposium 5: Complex Issues in Cardiology chairs: H. Darius (Berlin, DE) B. Pieske (Graz, AT) 08:00-08:30 The Non-Revascularizable Patient: Available Options (D. Gulba, Düren, DE) 08:30-09:00 Antithrombotic Therapy in the Elderly: Appropriate Utlization of Efficacy and Risks: (F. Andreotti, Rome, IT) 09:00-09:30 Genetic Profiling Why It Is the Future (S. Close-Kirkwood, Indianapolis, US) 09:30-10:00 Break, Exhibition 10:00-12:30 Symposium 6: Interventional Cardiology chairs: D. Gulba (Düren, DE) W. Benzer (Feldkirch, AT) 10:00-10:30 Left Main and Proximal Bifurcations (R. Wijns, Aalst, BE) 10:30-10:45 Case #7 (T. Brunner, Wr. Neustadt, AT) 10:45-11:15 Multivessel Disease: When to Intervene, When to Stay Conservative (O. Pachinger, Innsbruck, AT) 11:15-11:30 Case #8 (I. Lang, Vienna, AT) 11:30-12:00 The Optimal Management of Restenosis: Challenges and Opportunities (U. Zeymer, Ludwigshafen, DE) 12:00-12:30 Cases #9 and #10 (H. Alber, Innsbruck, AT) 12:30-14:00 Lunch Break 13:00-14:00 Moderated Poster Discussion B Moderator: K. Janata (Vienna, AT) 14:00-15:30 Symposium 7: Antithrombotic Therapy in ACS News chairs: F.W.A. Verheugt (Amsterdam, NL) F. Andreotti (Rome, IT) 14:00-14:25 Pharmacogenetics and Pharamcogenomics of Thienopyridines (S. Close-Kirkwood, Indianapolis, US) 5
7 Monday, January 24, :25-14:45 Platelet Function Testing in Clopidogrel Treated Patients: How, When and Why? (J.-P. Collet, Paris, FR) 14:45-15:05 Triple Therapy After Coronary Stenting in Patients with Atrial Fibrillation (F.W.A. Verheugt, Amsterdam, NL) 15:05-15:30 New Antithrombotic Agents on the Horizon (H. Darius, Berlin, DE) 15:30-16:00 Break, Exhibition 16:00-18:00 Symposium 8: ST-Segement Elevation Myocardial Infarction chairs: H. Darius (Berlin, DE) R. De Caterina (Chieti, IT) 16:00-16:30 STEMI Networks: Room for Improvement (F. van de Werf, Leuven, B) 16:30-16:45 Case #11 (A. Geppert, Vienna, AT) 16:45-17:15 DES vs. BMS in STEMI: Have All the Issues Been Resolved? (H. Schühlen, Berlin, D) 17:15-17:30 Case #12 (W. Benzer, Feldkirch, AT) 17:30-18:00 Gaps in Evidence: Single or Multivessel Treatment in PPCI? (S.D. Kristensen, Aarhus, DK) 18:00-18:15 Break, Exhibition 18:15-19:30 Satellite Symposium: Old and New Agents for the New Revascularization Guidelines (sponsored by Eli Lilly/Daiichi Sankyo) Moderator: O. Pachinger (Innsbruck, AT) 18:15-18:45 TRITON TIMI-38 Substudies (H. Schühlen, Berlin, DE) 18:45-19:15 IIb or NOT IIb Future Indications for GP IIb/IIIa- Blockers (K. Huber, Vienna, AT) 19:15-19:30 Discussion 20:30 Social Evening 6
8 Tuesday, January 25, :00-09:00 Symposium 9: Cardiogenic Shock and the High-Risk Patient chairs: H. Schühlen (Berlin, DE) F.W.A. Verheugt (Amsterdam, NL) 08:00-08:30 IABP, Tandem heart and Impella in Shock: The Role of Mechanical Support Systems in Cardiogenic Shock (U. Zeymer, Ludwigshafen, DE) 08:30-09:00 What is New in the Guidelines? (A. Geppert, Vienna, AT) 09:00-10:00 Symposium 10: Biomarker Update 2011 (partially sponsored by Brahms) chairs: J. Wojta (Vienna, AT) R. De Caterina (Chieti, IT) 09:00-09:20 Biomarkers for Risk Stratification in ACS (C. Granger, Durham, USA) 09:20-09:40 Troponin and Copeptin in the Early Diagnostic of ACS (M. Möckel, Berlin, DE) 09:40-10:00 Biomarkers for Secondary Prevention (S. Blankenberg, Mainz, DE) 10:00-10:30 Break, Exhibition 10:30-11:30 Symposium 11: Ticagrelor Is it the Ultimative Strategy in ACS chairs: S.D. Kristensen (Aarhus, DK) H. Darius (Berlin, DE) 10:30-11:00 Ticagrelor The New Player (K. Huber, Vienna, AT) 11:00-11:30 The PLATO Substudies (F.W.A. Verheugt, Amsterdam, NL) 11:30-12:30 Lunch Break 7
9 Tuesday, January 25, :30-14:30 Symposium 12: New Devices and Experiences in Interventional Cardiology (partially sponsored by Abbott Cardiovascular, Biosensors/Zodl MTP e.u., Biotronik, Cordis/Johnson&Johnson, Ardian) chairs: O. Pachinger (Innsbruck, AT) C. Granger (Durham, US) 12:30-12:50 The MITRACLIP Experience: An Update (W. Tkalec, Linz, AT) 12:50-13:10 From Biodegradable Polymer Stents to Polymer Free Stents Insights Into the LEADERS and BIOFREEDOM FIM Trials (G. Delle-Karth, Vienna, AT) 13: Impact of the Polymer on Late Outcome after DES Implantation (J. Mehilli, Munich, DE) 13:30-13:50 Limus vs. Paclitaxel The Truth (G. Christ, Vienna, AT) 13:50-14:10 DES Implantation in Complex Subjects: Does the DES Type Matter? (J. Mehilli, Munich. DE) 14:10-14:30 Renal Plexus Ablation: Fighting Hypertension (F. Mahfoud, Hamburg/Saar DE) 14:30-15:00 Coffee Break 15:00-17:00 Symposium 13: Metabolic Disease and the Heart chairs: J. Wojta (Vienna, AT) T. Wascher (Vienna, AT) 15:30-15:50 The risk of thrombotic and of bleeding events in diabetic subjects treated with antiplatelet agents (R. De Caterina, Chieti, IT) 15:50-16:05 Case #13 (C. Saely, Feldkirch, AT) 16:05-15:25 Current Status of HDL-Elevating Therapies Promises and Pitfalls (H. Drexel, Feldkirch, AT) 16:25-16:40 Case #14 (C. Saely, Feldkirch, AT) 16:40-17:00 Blood Pressure, Lipds, HbA1C: How low should we go? (T. Wascher, Vienna, AT) 8
10 SPONSORS (as per December 1, 2010) ABBOTT Vascular ARDIAN ASTRAZENECA BAYER Austria BIOSENSORS / Johannes ZODL MTP e.u. BOSTON SCIENTIFIC BOEHRINGER INGELHEIM BRAHMS CORDIS, a Johnson & Johnson company ELI LILLY ELI LILLY / DAIICHI SANKYO MEDTRONIC MERCK, SHARP & DOHME PFIZER PHILIPS MED. SYST. GMBH ST. JUDE THE MEDICINES COMPANY Z Zodl MTP e.u.
11 INVITED FACULTY Hannes ALBER (Austria) Felicita ANDREOTTI (Italy) Werner BENZER (Austria) Stefan BLANKENBERG (Germany) Martin BORGGREFE (Germany) Thomas BRUNNER (Austria) Günter CHRIST (Austria) Sandra CLOSE-KIRKWOOD (USA) Jean-Phillip COLLET (France) Harald DARIUS (Germany) Raffaele DE CATERINA (Italy) Georg DELLE-KARTH (Austria) Heinz DREXEL (Austria) Alexander GEPPERT (Austria) Bernard GERSH (USA) Martin GRABENWÖGER (Austria) Chris GRANGER (USA) Michael GRIMM (Austria) Dietrich GULBA (Germany) Kurt HUBER (Austria) Karin JANATA (Austria) Steen Dalby KRISTENSEN (Denmark) Irene LANG (Austria) Felix MAHFOUD (Germany) Julinda MEHILLI (Germany) Bernhard MEIER (Switzerland) Bela MERKELY (Hungary) Martin MÖCKEL (Germany) Hans-Joachim NESSER (Austria) Otmar PACHINGER (Austria) Burkert PIESKE (Austria) Gerhard PÖLZL (Austria) Christoph SAELY (Austria) Helmut SCHÜHLEN (Germany) Udo SECHTEM (Germany) Wolfgang TKALEC (Austria) Frans VAN DE WERF (Belgium) Freek VERHEUGT (The Netherlands) Thomas WASCHER (Austria) Petr WIDIMSKY (Czech Republic) Stephan WINDECKER (Switzerland) William WIJNS (Belgium) Johann WOJTA (Austria) Uwe ZEYMER (Germany) Printed in Austria by: ROBIDRUCK, A-1200 Vienna 1
Integrated Management of Acute and Chronic Cardiovascular Disease
15 th International Meeting Integrated Management of Acute and Chronic Cardiovascular Disease www.cardio-congress.com ORGANIZERS: KURT HUBER (Austria) HARALD DARIUS (Germany) BERNARD GERSH (USA) OTMAR
More information10 th International Meeting Coronary Reperfusion. Secondary Prevention FINAL PROGRAM. Burghotel Oberlech Austria March 21 26, 2009
10 th International Meeting Coronary Reperfusion & Secondary Prevention DIRECTORS: H. DARIUS B. GERSH K. HUBER A. ROSS TOPICS: Acute Coronary Syndromes Antiplatelet Agents Antithrombins Atrial Fibrillation
More informationCoronary Reperfusion. & Secondary Prevention FINAL PROGRAM. Oberlech, Austria April 5 10, 2008 H. DARIUS K. HUBER A. M.
Coronary Reperfusion & Secondary Prevention DIRECTORS: H. DARIUS K. HUBER A. M. ROSS TOPICS: Acute Coronary Syndromes Antiplatelet Agents Antithrombins Cardiac Resynchronization Chronic Angina Controversies
More informationIntegrated Management of Acute and Chronic Cardiovascular Disease
13 th International Meeting Integrated Management of Acute and Chronic Cardiovascular Disease www.cardio-congress.com ORGANIZERS: KURT HUBER (Austria) BERNARD GERSH (USA) HARALD DARIUS (Germany) OTMAR
More informationIntegrated Management of Acute and Chronic Cardiovascular Disease
17 th International Meeting Integrated Management of Acute and Chronic Cardiovascular Disease www.cardio-congress.com ORGANIZERS: KURT HUBER (Austria) HARALD DARIUS (Germany) BERNARD GERSH (USA) CHRIS
More informationCoronary Reperfusion. & Secondary Prevention. Oberlech, Austria April 14 19, 2007 H. DARIUS K. HUBER A. M. ROSS P R O R A A ORGANIZERS:
Coronary Reperfusion & Secondary Prevention ORGANIZERS: H. DARIUS K. HUBER A. M. ROSS Oberlech, Austria April 14 19, 2007 TOPICS: Acute Coronary Syndromes Antithrombins Antiplatelet Therapy ASD+PFO Closure
More informationIntegrated Management of Acute and Chronic Coronary Artery Disease
20 th International Meeting Integrated Management of Acute and Chronic Coronary Artery Disease From Prevention to Intervention ORGANIZERS: KURT HUBER (Austria) HARALD DARIUS (Germany) BERNARD GERSH (USA)
More informationIntegrated Management of Acute and Chronic. Coronary Artery Disease. PRELIMINARY PROGRAM From Prevention to Intervention
19 th International Meeting Integrated Management of Acute and Chronic Coronary Artery Disease From Prevention to Intervention ORGANIZERS: KURT HUBER (Austria) HARALD DARIUS (Germany) BERNARD GERSH (USA)
More informationIntegrated Management of Acute and Chronic. Coronary Artery Disease. FINAL PROGRAM From Prevention to Intervention
19 th International Meeting Integrated Management of Acute and Chronic Coronary Artery Disease From Prevention to Intervention ORGANIZERS: KURT HUBER (Austria) HARALD DARIUS (Germany) BERNARD GERSH (USA)
More informationDEADLINE FOR ABSTRACTS
summit 2012 Update on Thrombosis Meeting of the Working Group on Thrombosis European Society of Cardiology Pre-Final Program Thrombosis Thrombosis Main Topics Acute Coronary Syndromes Antiplatelet Agents
More informationIntegrated Management of Acute and Chronic Cardiovascular Disease
18 th International Meeting Integrated Management of Acute and Chronic Cardiovascular Disease ORGANIZERS: HARALD DARIUS (Germany) BERNARD GERSH (USA) CHRISTOPHER GRANGER (USA) KURT HUBER (Austria) OTMAR
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Chairpersons Christian W. Hamm Medical Clinic
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationEAPCI: Biodegradable Scaffolds-Writers 2016
Baumbach Andreas Byrne Robert - Medicines Company : Drugs (2015) - Abbott Vascular : Stents (2015) - Abbott Vascular : Stent (2015) - Boston Scientific : Medical devices (2015) - Biotronik : Medical devices
More informationAcute coronary syndromes A European viewpoint. Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT
Acute coronary syndromes A European viewpoint Felicita Andreotti, MD PhD FESC Catholic University Hospital Cardiovascular Diseases - Rome, IT Potential conflicts of interest In the past 2 years Felicita
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationESC Sessions of Interest, Satellite Symposia, Poster Sessions
ESC Sessions of Interest, Satellite Symposia, Poster Sessions 1 Program at a glance* Date/ Time Event Location Saturday 30 Aug 2014 11:00-16.00 Poster session 1: PCI Outcomes in the spotlight One-year
More informationC. W. Hamm, B. Cremers, H. Moellmann, S. Möbius-Winkler, U. Zeymer, M. Vrolix, S. Schneider, U. Dietz, M. Böhm, B. Scheller
Paclitaxel-Eluting PTCA-Balloon in Combination with the Coroflex Blue Stent vs the Sirolimus Coated Cypher Stent in the Treatment of Advanced Coronary Artery Disease C. W. Hamm, B. Cremers, H. Moellmann,
More informationSHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?
SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI? Kurt Huber, MD 3 Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminenhospital, Vienna, Austria Disclosures DISCLOSURE
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationDual Antiplatelet Therapy: Time for a Paradigm Shift?
Dual Antiplatelet Therapy: Time for a Paradigm Shift? 5 years after PLATO Experience from the Daily Clinical Practice Hans Rickli Goals with antithrombotic treatment Acute coronary syndrome Risk reduction
More informationAdditional Contributor: Glenn Levine (USA).
2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationThe 2 nd Royal Brompton & Harefield Christmas Postgraduate Course
The 2 nd Royal Brompton & Harefield Christmas Postgraduate Course The Royal Society of Medicine, 1 Wimpole St, Marylebone, London December 17 th 18 th, 2018 Course Directors Prof. Thomas F. Lüscher, FRCP,
More informationAntithrombotic Therapy in ACS Pretreatment in STEMI. Christian W. Hamm Kerckhoff Heart & Thorax Center Bad Nauheim Germany
Antithrombotic Therapy in ACS Pretreatment in STEMI Christian W. Hamm Kerckhoff Heart & Thorax Center Bad Nauheim Germany Potential conflicts of interest Speaker s name: Christian W. Hamm I have the following
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationAdvance Programme ACUTE CARDIOVASCULAR CARE2015 EUROPEAN SOCIETY OF CARDIOLOGY
Advance Programme ACUTE CARDIOVASCULAR CARE2015 EUROPEAN SOCIETY OF CARDIOLOGY 08:30 10:00 Saturday 17 October 2015 Zeremoniensaal Prinz Eugen Saal Rittersaal Gartensaal Neurologic emergencies Acute cardiovascular
More informationPCHF. A novel course in heart failure management POSTGRADUATE COURSE IN HEART FAILURE
PCHF POSTGRADUATE COURSE IN HEART FAILURE A novel course in heart failure management Certified by the European Society of Cardiology (ESC) and the University of Zurich. Based on the new curriculum of the
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationFreedom to Treat Your High Bleeding Risk Patients. Tim Kinnaird University Hospital of Wales, Cardiff, UK
Freedom to Treat Your High Bleeding Risk Patients Tim Kinnaird University Hospital of Wales, Cardiff, UK Relevant Disclosures Honoraria for lectures from: o Eli Lilly & Co, Daiichi Sankyo, Boehringer,
More informationWHICH ANTITHROMBOTIC REGIMEN? Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France.
TAVI WITH ATRIAL FIBRILLATION: WHICH ANTITHROMBOTIC REGIMEN? G. MONTALESCOT (PARIS, FR) Action Study Group Institut de Cardiologie - Pitié-Salpêtrière Hospital Paris, France www.action-cœur.org Dr. Montalescot
More informationPreliminary Programme
Preliminary Programme The scientific programme comprises various styles of presentations and sessions, each offering a unique opportunity to amass new and important scientific information. Optimal management
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationWorking Group on Thrombosis of the European Society of Cardiology
Working Group on Thrombosis of the European Society of Cardiology WG on THROMBOSIS (WG18) NUCLEUS MEMBERS 2006-2008 Chairman: Kurt HUBER Director, 3rd Dept.of Medicine Cardiology and Emergency Wilhelminenhospital
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationPRELIMINARY PROGRAM. 14:10-15:00 Session I: My Personal Experience CT/MR Chair: Herbert Frank Tulln, Austria Udo Hoffmann Boston, USA
PRELIMINARY PROGRAM Thursday 5 October 2017 14:00 Welcome 14:10-15:00 Session I: My Personal Experience CT/MR Chair: 14:10 14:35 Tips and Tricks CMR Holger Thiele Leipzig, Germany 14:35 15:00 Tips and
More informationState of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
More informationLisette Okkels Jensen
A Randomized Trial Comparing a Polymer- Free Coronary Drug-Eluting Stent With an Ultra-Thin Strut Bioresorbable Polymer- Based Drug-Eluting Stent in an All-Comers Patient Population Lisette Okkels Jensen
More informationRandomized comparison of a sirolimus-eluting stent with a biolimus-eluting stent in patients treated with PCI: the SORT OUT VII trial
euro P C R Randomized comparison of a sirolimuseluting stent with a biolimuseluting stent in patients treated with PCI: the SORT OUT VII trial Lisette Okkels Jensen, Per Thayssen, Michael Maeng, Jan Ravkilde,
More informationISCHEMIC HEART DISEASE
ESC CONGRESS HIGHLIGHTS ISCHEMIC HEART DISEASE Francesco Cosentino (Stockholm, S) Declaration of Interest Advisory Board/Speaker: AstraZeneca, Roche, Boehringer-Ingelheim, Bristol-Myers Squibb, Merck,
More informationEUROPEAN HEART RHYTHM ASSOCIATION A Registered Branch of the ESC
Application for the following position in the EHRA Board: (please specify) SECRETARY 1. Your Identity Title: Professor Dr., PhD, FESC, FACC Family Name(s): HATALA First Name(s): ROBERT Birth Date: 21 st
More informationScope of the Problem: DAPT and Triple Therapy after Stenting
Scope of the Problem: DAPT and Triple Therapy after Stenting Kurt Huber, MD, FESC, FACC 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Session, August 30, 2010,
More informationStudy design: multicenter, randomized, open-label trial following a PROBE design
Subgroup Analysis from the RE-DUAL PCI Trial Dual Antithrombotic Therapy with in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Jonas Oldgren, Philippe Gabriel Steg, Stefan
More informationANNUAL REPORT
Identification Working Group on: Cardiovascular Pharmacotherapy Nucleus Composition (Sept 2014-Sept 2016) (Precise name, surname and country) Chairperson:... Vice-chairperson & Secretary... Past Chairperson...
More informationKey recommendations on antithrombotic and lipid lowering therapy from the 2017 guidelines of the European Society of Cardiology
Key recommendations on antithrombotic and lipid lowering therapy from the 2017 guidelines of the European Society of Cardiology Univ.-Prof. Dr. med. Christine Espinola-Klein Department of Angiology Center
More informationDES in primary PCI for STEMI: contra
DES in primary PCI for STEMI: contra Philippe Gabriel Steg Department of Cardiology Hôpital Bichat Claude Bernard, AP-HP Université Paris VII Denis Diderot INSERM U-698 Paris, France Ph. Gabriel Steg -
More informationNational Intervention Council
National Intervention Council Cardiological Society of India Registry Performa for Coronary, Non- Coronary & Peripheral Interventions Period January 1st 2016 to December 31 st 2016 Dr. (Prof.) N.N. Khanna
More informationFOCUS: Valve Medical University Innsbruck INNSBRUCK AUSTRIA SEPT ,
SAVE THE DATE FOCUS: Valve 2017 9 th Training Course for Minimally Invasive Heart Valve Surgery Medical University Innsbruck INNSBRUCK AUSTRIA SEPT. 10 13, 2017 Dear colleagues! The increasing importance
More informationRivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction
Journal of the American College of Cardiology Vol. 61, No. 18, 2013 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.066
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationPCHF A NOVEL COURSE IN HEART FAILURE MANAGEMENT POSTGRADUATE COURSE IN HEART FAILURE LONDON. January 2019 to October 2020
PCHF POSTGRADUATE COURSE IN HEART FAILURE LONDON A NOVEL COURSE IN HEART FAILURE MANAGEMENT January 2019 to October 2020 Venue: The Royal Society of Medicine, 1 Wimpole Street, Marylebone, London, UK Endorsed
More informationBéla MERKELY MD, PhD, DSc, FESC. Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment
Semmelweis University Heart Center Budapest, Hungary Béla MERKELY MD, PhD, DSc, FESC Stent thrombosis: patophysiology, predisposing factors, definition, classification, prevention and treatment 10th Interventional
More information3 rd BELGIAN LEFT ATRIAL APPENDAGE OCCLUSION MEETING. Friday Hotel Dolce La Hulpe Brussels
3 rd BELGIAN LEFT ATRIAL APPENDAGE OCCLUSION MEETING Friday 23.11.2018 Hotel Dolce La Hulpe Brussels MEETING OBJECTIVES Dear Colleagues, Oral anticoagulation remains the mainstay of therapy for stroke
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationUniversity of Leipzig Heart Center
Randomized comparison of intraaortic balloon counterpulsation versus optimal medical therapy in addition to early revascularization in acute myocardial infarction complicated by cardiogenic shock Holger
More informationUpdate interventional Cardiology Hans Rickli St.Gallen
Update interventional Cardiology 2012 Hans Rickli St.Gallen 26.11.2012 Review of Literature ESC-Highlights TCT/AHA-Highlights Update interventional cardiology 2012 Structural Heart Disease Transcatheter
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationSTEMI Linee guida ESC Maddalena Lettino, Italy
STEMI Linee guida ESC 2017 Maddalena Lettino, Italy Disclosure Speaker fee: Aspen, Astra Zeneca, BMS, Boehringer, Eli Lilly, DaichiiSankio, Bayer, Pfizer, Sanofi Advisory board member: Astra Zeneca, Eli
More informationSCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?
SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding
More informationECMELLA. Associate Prof. Dirk Westermann, MD, PhD. Department of General and Interventional Cardiology Hamburg, Germany. Department of Medicine
ACS in Women ECMELLA Combined Impella and ECMO in Cardiogenic Shock Prof. Peter Clemmensen, MD, DMSc, FESC, FSCAI Associate Prof. Dirk Westermann, MD, PhD University Heart Center Hamburg-Eppendorf Department
More informationThe Universal Definition of Myocardial Infarction 3 rd revision, 2012
The Universal Definition of Myocardial Infarction 3 rd revision, 2012 Joseph S. Alpert, MD Professor of Medicine, University of Arizona College of Medicine, Tucson, AZ; Editor-in-Chief, American Journal
More informationESMO Symposium on Immuno-Oncology Programme book
IMMUNO-ONCOLOGY SYMPOSIUM ESMO Symposium on Immuno-Oncology Programme book Advances in cancer immunotherapy; From vaccines to antibodies and cell therapies Geneva Switzerland 15-16 NOVEMBER 2013 esmo.org
More informationDrug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2
Drug-Coated Balloons for Small Coronary Artery Disease: BASKET-SMALL 2 Raban V. Jeger,Ahmed Farah, Marc-Alexander Ohlow, Norman Mangner, Sven Möbius-Winkler, GregorLeibundgut, Daniel Weilenmann, JochenWöhrle,
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationTechnical Aspects and Clinical Indications of FFR
Technical Aspects and Clinical Indications of FFR Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst - OLV Clinic Aalst, Belgium Potential conflicts of interest Consulting fees and honoraria on
More informationPRELIMINARY PROGRAMME
PRELIMINARY PROGRAMME 26 May 2017 ITALIAN LANGUAGE SYMPOSIUM PHARMACOLOGY IN INTERVENTIONAL CARDIOLOGY DAPT AFTER PCI 10.00 CONTROVERSY 1 - P2Y12 INHIBITION AFTER PCI IN STABLE PATIENTS Clopidogrel remains
More informationOptimal antithrombotic therapy:
Optimal antithrombotic therapy: upstream and during primary PCI. Steen D Kristensen, MD, DMSc, FESC Professor and Consultant Interventional Cardiologist Aarhus University, Denmark UNIVERSITY OF AARHUS
More information2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation
European Heart Journal 2012 doi:10.1093/eurheartj/ehs253 ESC 2012 2012 focussed update of the ESC Guidelines for the Management of Atrial Fibrillation An update of the 2010 ESC Guidelines for the Management
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationDisclosure. Financial disclosure: National Advisory Board & Research Grant from Boehringer-Ingelheim
Randomised Dabigatran Etexilate Dose Finding Study In Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors For Cardiovascular Complications Also Receiving Aspirin and Clopidogrel
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationThis educational programme has received unrestricted grants from:
This educational programme has received unrestricted grants from: Schiller Reomed AG DAIICHI SANKYO (SCHWEIZ) AG gsk GlaxoSmithKline The sponsors were not involved in the development of this programme,
More informationJoint Congress PAFCIC Complex PCI meeting
Joint Congress PAFCIC Complex PCI meeting October 18-20, 2018, Nairobi, KENYA The Program : - Interactive sessions - Practical workshops - Key note lectures - Live transmissions - Poster and oral presentations
More informationBelgian Society on Thrombosis and Haemostasis
BELGIAN SOCIETY Belgian Society on Thrombosis and Haemostasis Final Announcement ANNUAL MEETING 25-26 November 2010 Het Pand Gent Belgium Local organizer: Katrien Devreese Coagulation Laboratory - Ghent
More informationSeptember 14 th 16 th, 2017 Innsbruck, Austria
MUSCULOSKELETAL SONOGRAPHY COURSE FOR RHEUMATOLOGISTS - BASIC LEVEL - September 14 th 16 th, 2017 Innsbruck, Austria This course is scientifically endorsed by: GENERAL INFORMATION Course opening: Thursday,
More informationJournal of the American College of Cardiology
Advertisement Journal of the American College of Cardiology Volume 72, Issue 3, July 2018 DOI: 10.1016/j.jacc.2018.04.063 PDF Article Download Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory
More informationUPDATES FROM THE 2018 ANTIPLATELET GUIDELINES
UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in
More informationP2Y 12 blockade. To load or not to load before the cath lab?
UPDATE ON ANTITHROMBOTICS IN ACUTE CORONARY SYNDROMES P2Y 12 blockade. To load or not to load before the cath lab? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria,
More information8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference Dubai: October Acute Coronary Syndromes
8th Emirates Cardiac Society Congress in collaboration with ACC Middle East Conference 2017 Dubai: 19-21 October 2017 Acute Coronary Syndromes Antonio Colombo Centro Cuore Columbus and S. Raffaele Scientific
More informationOptimal lenght of DAPT in different clinical scenarios
Optimal lenght of DAPT in different clinical scenarios After PCI with DES in the light of recent and ongoing studies Dr Grégoire Rangé / CH Chartres / France DAPT duration depend on the evolution of risk
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationBern-Rotterdam Cohort Study
Bern-Rotterdam Cohort Study Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents Lorenz
More informationEffect of REG1 Anticoagulation System versus Bivalirudin on Cardiovascular Outcomes Following PCI: The REGULATE-PCI Randomized Clinical Trial
Effect of REG1 Anticoagulation System versus Bivalirudin on Cardiovascular Outcomes Following PCI: The REGULATE-PCI Randomized Clinical Trial Roxana Mehran, John Alexander, and Michael Lincoff on the Behalf
More informationACCESS-EUROPE Phase I
ACCESS-EUROPE Phase I A Post Market Study of the MitraClip System for the Treatment of Significant Mitral Regurgitation in Europe: Analysis of Outcomes at 1 Year Wolfgang Schillinger, MD on behalf of the
More informationPlatelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary
Platelet function testing to guide P2Y 12 -inhibitor treatment in ACS patients after PCI: insights from a national program in Hungary Dániel Aradi MD PhD Interventional Cardiologist Assistant professor
More informationSTEMI 2014 YAHYA KIWAN. Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital
STEMI 2014 YAHYA KIWAN Consultant Cardiologist Head Of Cardiology Belhoul Specialty Hospital Aspiration Thrombectomy Manual aspiration thrombectomy is reasonable for patients undergoing primary PCI. I
More information8 live surgeries in 3D - workshops - wetlabs. Medical University Innsbruck INNSBRUCK AUSTRIA SEPT , 2018
PRELIMINARY PROGRAM FOCUS FOCUS: Valve 2018 8 live surgeries in 3D - workshops - wetlabs 10 th Training Course for Minimally Invasive Heart Valve Surgery Medical University Innsbruck INNSBRUCK AUSTRIA
More informationRecognizing the High Risk NSTEMI Patient for Early Appropriate Therapy
Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationHF/HTX. Tuesday, April 10, 2018 MEDITERRANEE ABC. In HEART FAILURE AND CARDIAC TRANSPLANTATION. Scientific Program Committee.
ISHLT ACADEMY In HEART FAILURE AND CARDIAC TRANSPLANTATION Tuesday, April 10, 2018 MEDITERRANEE ABC 7:55 am 5:30 PM Scientific Program Committee CHAIR: Shelley Hall, MD, Baylor University CO-CHAIR: Lavanya
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationWhat s new in Cardiovascular medicine? Dr Stephen Dorman Consultant Cardiologist, Morriston Cardiac Centre Mid & West Cardiac Network Lead
What s new in Cardiovascular medicine? Dr Stephen Dorman Consultant Cardiologist, Morriston Cardiac Centre Mid & West Cardiac Network Lead A year in review... Primary & sceondary Prevention IHD & Coronary
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More information7 th Conference of Transcatheter Heart Valve Therapies
7 th Conference of Transcatheter Heart Valve Therapies May 18-19, 2018, Athens Hilton Athens, Greece Course Directors Stratis Pattakos MD Konstantinos Spargias MD Panos Vardas MD Co-Directors Nick Bouboulis
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationCONTENT. 1. Acute Cardiac Care Committee Congress Dates & Venue Scientific Scientific sessions overview... 5 Abstracts...
1 Page CONTENT 1. Acute Cardiac Care Committee... 3 2. Congress Dates & Venue... 4 3. Scientific... 5 Scientific sessions overview... 5 Abstracts... 6 4. Registration/Attendees... 8 5. Sponsors... 12 6.
More information